Developer docs
API playgroundTry for free, no card

Search company profiles

Clarity Pharmaceuticals

Full company profile

uuid0000aw7

Namestring
Clarity Pharmaceuticals
Legal namestring
Clarity Pharmaceuticals
Company typeenum
Public
Founded yearint
2010
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersSydney, Australia
HQ citystring
Sydney
HQ countrystring
Australia
HQ regionstring
Oceania
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
radiopharmaceutical products, targeted copper theranostics, prostate cancer imaging, PSMA-targeted therapy, oncology radiodiagnostics
Industry3 codes
PRIMARYHLAIAGAC
Theranostic Radiopharmaceutical Platforms (Paired Dx/Tx)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYHLAIAGAB
Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)
NAICS code3 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
  • In-Vitro Diagnostic Substance Manufacturing325413
SIC code2 codes
  • Pharmaceutical Preparations2834
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Radiopharmaceuticals
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Radiopharmaceutical Product Sales (Anticipated)
TypeOne Time License
Description

Clarity is a clinical-stage company with no current product revenue. Upon successful completion of Phase III trials (AMPLIFY, CLARIFY) and FDA NDA approval, Clarity plans to commercialise 64Cu-SAR-bisPSMA as a next-generation PSMA PET diagnostic imaging agent for prostate cancer, and subsequently 67Cu-SAR-bisPSMA as a therapeutic agent. Revenue will be generated from product sales to hospitals, imaging centres, and nuclear medicine departments. The company has established large-scale manufacturing supply agreements with Theragenics, Nucleus RadioPharma, Nusano, UQ AIBN, and SpectronRx to support commercial launch capacity of over 2 million doses per year.

claritypharmaceuticals.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Clarity Pharmaceuticals is a clinical-stage radiopharmaceutical company developing next-generation Targeted Copper Theranostics (TCT) based on its proprietary SAR (Sarcophagine) chelator platform. Its products pair copper-64 (for diagnostic PET imaging) and copper-67 (for therapy) with tumour-targeting molecules, including SAR-bisPSMA for prostate cancer, SARTATE for neuroendocrine tumours and neuroblastoma, and SAR-Bombesin for pan-cancer indications. Upon FDA approval, finished doses will be supplied directly to hospitals, imaging centres and nuclear medicine departments.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 64Cu-SAR-bisPSMA detected mean 1.26 lesions per patient vs 0.48 for 68Ga-PSMA-11 (p<0.0001) in the Co-PSMA head-to-head Phase II trial, with 63 total lesions detected vs 24.
+5 more records
Product overview1 text field

Clarity Pharmaceuticals is a clinical-stage radiopharmaceutical company developing a portfolio of Targeted Copper Theranostics (TCT) based on its proprietary SAR Technology platform. The platform uses copper isotopes—copper-64 for diagnostic imaging and copper-67 for therapy—in combination with targeting molecules. The core products include SAR-bisPSMA (for prostate cancer), SARTATE (for neuroendocrine tumors and neuroblastoma), and SAR-Bombesin (pan-cancer product). The lead product SAR-bisPSMA is in Phase III registrational trials for diagnostic imaging and Phase II for therapeutic use. Preclinical pipeline includes SAR-bisFAP (pan-cancer) and SAR-trastuzumab (breast cancer). The company operates multiple clinical trials across the US and Australia.

Product and service1 record
1SAR-bisPSMA Platform
Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-04-14
Description

Commercial Manufacturing Agreement for Cu-64 SAR-bisPSMA production. Covers Nucleus RadioPharma's existing facility in Rochester, Minnesota (50,000 doses/year) and a planned facility in Spring House, Pennsylvania opening in 2028 (600,000 doses/year), enabling nationwide US distribution and expansion to select international markets including Europe. A key step in Clarity's manufacturing buildout ahead of anticipated commercial launch pending FDA NDA approval.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-03-25
Description

Large-scale Manufacturing Supply Agreement for copper-64 production at Theragenics' 134,000 sq ft facility with 14 cyclotrons near Atlanta, Georgia. Capacity of ~100Ci copper-64 per day per cyclotron translates to ~2,000 patient doses per day per cyclotron, with a 48-hour shelf life. The Atlanta facility is a major US transport hub. This agreement complements existing copper-64 supply with SpectronRx and Nusano, enhancing Clarity's broad network of high-volume copper-64 manufacturers in distinct US geographies.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-10-16
Description

Three-year copper-67 supply agreement with Utah-based Nusano, a company building an isotope production facility in Utah. Copper-67 is the therapeutic isotope used in 67Cu-SAR-bisPSMA for prostate cancer therapy. Supply expected to start in mid-2026, supporting Clarity's Phase III trials and commercial launch. Nusano's new production methods aim to ensure a sustainable and scalable supply of copper-67.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-02-11
Description

Supply Agreement for clinical-grade GMP trastuzumab biosimilar (EG12014) to support the development of 64/67Cu-SAR-trastuzumab for HER2-positive breast cancer. EirGenix's trastuzumab (marketed as EIRGASUN in Taiwan, partnered with Sandoz as Herwenda in Europe) secures clinical supply for Clarity's radioimmunotherapy (RIT) program. EirGenix's Chairman commented that RIT using copper-67 is a promising avenue for next-generation antibody therapies.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-02-11
Description

Academic collaboration with the University of Melbourne on pioneering work combining trastuzumab antibody with Clarity's SAR chelator for copper-64/67 radiolabelling, resulting in the 64/67Cu-SAR-trastuzumab preclinical asset.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-01-01
Description

Copper-64 supply agreement with UQ's Australian Institute for Bioengineering and Nanotechnology (AIBN). The AIBN houses an on-site cyclotron and state-of-the-art radiochemistry facilities supplying copper-64 weekly to Australian clinical trial sites. Supports Phase III CLARIFY and AMPLIFY trials in Australia, the Co-PSMA IIT at St Vincent's Hospital Sydney, and the SECuRE theranostic trial. Also supports preclinical programs including SAR-bisFAP and SAR-trastuzumab.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

Clarity is an active participant in the Australian Research Council (ARC) Hub for Advanced Manufacture of Targeted Radiopharmaceuticals (AMTAR), a collaborative R&D initiative advancing radiopharmaceutical manufacturing in Australia.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Novartis commercializes Pluvicto (Lu-177 PSMA-617) for mCRPC and Lutathera for NETs — the most direct approved competitors to Clarity's SAR-bisPSMA and SARTATE. Both target the same indications with radioligand therapy, and Novartis' commercial scale and physician relationships set the competitive benchmark.

TypeDirect peer
Description

Telix is the most directly comparable clinical/commercial radiopharmaceutical peer, with approved Illuccix (Ga-68 PSMA-11 PET) for prostate cancer imaging and a pipeline of PSMA-targeted therapies. Same target class, similar distribution model to hospitals/imaging centers, and overlapping indications make it Clarity's closest competitor for both share-of-voice and commercial share.

TypeDirect peer
Description

Lantheus markets Pylarify (F-18 DCFPyL) for PSMA PET imaging and has a PSMA-targeted radioligand therapy (PNT2002) in development. Direct competitor in prostate cancer imaging with established US commercial infrastructure and similar radiopharmaceutical business model.

TypeBroad incumbent
Description

Bayer acquired PSMA-617 rights and operates in the PSMA radioligand space alongside its broader oncology franchise. Broad incumbent with deep capital and a radioligand therapy competing directly with Clarity's SAR-bisPSMA therapeutic program in mCRPC.

TypeDirect peer
Description

POINT Biopharma develops PSMA-targeted radioligand therapies (including PNT2002 in collaboration with Lantheus). Directly comparable as a clinical-stage radiopharmaceutical company targeting prostate cancer with Lu-177-based therapies.

TypeDirect peer
Description

Fusion Pharmaceuticals is a clinical-stage radiopharmaceutical company developing targeted alpha therapies (actinium-225) across multiple tumor types. Comparable business model, technology platform approach, and oncology focus make it a relevant emerging peer.

TypeEmerging player
Description

Actinium develops antibody-radionuclide conjugates for hematologic cancers using actinium-225. Comparable as a clinical-stage radiopharmaceutical company with platform technology, though focused on different isotopes and indications.

TypeBroad incumbent
Description

Bracco is a global diagnostic imaging company with a radiopharmaceutical portfolio (including Ga-68 PSMA agents through Blue Earth Diagnostics). Broad incumbent with established imaging distribution infrastructure and overlapping prostate cancer imaging products.

TypeBroad incumbent
Description

Curium is one of the world's largest nuclear medicine companies, manufacturing and distributing diagnostic radiopharmaceuticals including SPECT and PET agents. Relevant as a manufacturing and distribution competitor for hospital/nuclear medicine supply, with established relationships that Clarity's commercial team will compete against.

TypeBroad incumbent
Description

GE HealthCare has a major radiopharmaceutical and PET imaging franchise, including manufacturing capacity and emerging theranostic partnerships. Broad incumbent whose scale in nuclear medicine supply and imaging infrastructure represents both competitive pressure and potential partnership optionality.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers11 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance5 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Clarity Pharmaceuticals

Radiopharmaceuticalsclaritypharmaceuticals.com

Clarity Pharmaceuticals firmographics

Firmographics
Name
Clarity Pharmaceuticals
Legal name
Clarity Pharmaceuticals
Website
https://claritypharmaceuticals.com
Company type
Public
Founded year
2010
Operating status
Operating
Headcount range
51–100 employees
Ownership category
akta.pro rank

Clarity Pharmaceuticals industry classification

Industry
Product category
Radiopharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), In-Vitro Diagnostic Substance Manufacturing (325413)
SIC
Pharmaceutical Preparations (2834), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAIAGAC
Theranostic Radiopharmaceutical Platforms (Paired Dx/Tx)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYHLAIAGAB
Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)

Keywords

  • Radiopharmaceutical products
  • Targeted copper theranostics
  • Prostate cancer imaging
  • PSMA-targeted therapy
  • Oncology radiodiagnostics

Where Clarity Pharmaceuticals is headquartered

Location

Headquarters

HQ city
Sydney
HQ country
Australia
HQ region
Oceania

Offices4 records

Markets served

Clarity Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Radiopharmaceutical Product Sales (Anticipated): Clarity is a clinical-stage company with no current product revenue. Upon successful completion of Phase III trials (AMPLIFY, CLARIFY) and FDA NDA approval, Clarity plans to commercialise 64Cu-SAR-bisPSMA as a next-generation PSMA PET diagnostic imaging agent for prostate cancer, and subsequently 67Cu-SAR-bisPSMA as a therapeutic agent. Revenue will be generated from product sales to hospitals, imaging centres, and nuclear medicine departments. The company has established large-scale manufacturing supply agreements with Theragenics, Nucleus RadioPharma, Nusano, UQ AIBN, and SpectronRx to support commercial launch capacity of over 2 million doses per year.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels5 records

Clarity Pharmaceuticals product offering

Product offering

Core offering

Clarity Pharmaceuticals is a clinical-stage radiopharmaceutical company developing next-generation Targeted Copper Theranostics (TCT) based on its proprietary SAR (Sarcophagine) chelator platform. Its products pair copper-64 (for diagnostic PET imaging) and copper-67 (for therapy) with tumour-targeting molecules, including SAR-bisPSMA for prostate cancer, SARTATE for neuroendocrine tumours and neuroblastoma, and SAR-Bombesin for pan-cancer indications. Upon FDA approval, finished doses will be supplied directly to hospitals, imaging centres and nuclear medicine departments.

Product overview

Clarity Pharmaceuticals is a clinical-stage radiopharmaceutical company developing a portfolio of Targeted Copper Theranostics (TCT) based on its proprietary SAR Technology platform. The platform uses copper isotopes—copper-64 for diagnostic imaging and copper-67 for therapy—in combination with targeting molecules. The core products include SAR-bisPSMA (for prostate cancer), SARTATE (for neuroendocrine tumors and neuroblastoma), and SAR-Bombesin (pan-cancer product). The lead product SAR-bisPSMA is in Phase III registrational trials for diagnostic imaging and Phase II for therapeutic use. Preclinical pipeline includes SAR-bisFAP (pan-cancer) and SAR-trastuzumab (breast cancer). The company operates multiple clinical trials across the US and Australia.

Differentiator

Problem solved

Functional benefit

Products and services

  • SAR-bisPSMA Platform

Quantifiable outcome

  • 64Cu-SAR-bisPSMA detected mean 1.26 lesions per patient vs 0.48 for 68Ga-PSMA-11 (p<0.0001) in the Co-PSMA head-to-head Phase II trial, with 63 total lesions detected vs 24.
  • +5 more outcomes

Companies that use Clarity Pharmaceuticals

Customer profile

Named customers11 records

Segments1 record

Ideal customer profiles1 record

Clarity Pharmaceuticals technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Clarity Pharmaceuticals partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered core and minor.

  • Nucleus RadioPharmacoreTechnology or Integration · 14 April 2026Commercial Manufacturing Agreement for Cu-64 SAR-bisPSMA production. Covers Nucleus RadioPharma's existing facility in Rochester, Minnesota (50,000 doses/year) and a planned facility in Spring House, Pennsylvania opening in 2028 (600,000 doses/year), enabling nationwide US distribution and expansion to select international markets including Europe. A key step in Clarity's manufacturing buildout ahead of anticipated commercial launch pending FDA NDA approval.
  • TheragenicscoreTechnology or Integration · 25 March 2026Large-scale Manufacturing Supply Agreement for copper-64 production at Theragenics' 134,000 sq ft facility with 14 cyclotrons near Atlanta, Georgia. Capacity of ~100Ci copper-64 per day per cyclotron translates to ~2,000 patient doses per day per cyclotron, with a 48-hour shelf life. The Atlanta facility is a major US transport hub. This agreement complements existing copper-64 supply with SpectronRx and Nusano, enhancing Clarity's broad network of high-volume copper-64 manufacturers in distinct US geographies.
  • NusanocoreTechnology or Integration · 16 October 2025Three-year copper-67 supply agreement with Utah-based Nusano, a company building an isotope production facility in Utah. Copper-67 is the therapeutic isotope used in 67Cu-SAR-bisPSMA for prostate cancer therapy. Supply expected to start in mid-2026, supporting Clarity's Phase III trials and commercial launch. Nusano's new production methods aim to ensure a sustainable and scalable supply of copper-67.
  • EirGenix, Inc.coreTechnology or Integration · 11 February 2025Supply Agreement for clinical-grade GMP trastuzumab biosimilar (EG12014) to support the development of 64/67Cu-SAR-trastuzumab for HER2-positive breast cancer. EirGenix's trastuzumab (marketed as EIRGASUN in Taiwan, partnered with Sandoz as Herwenda in Europe) secures clinical supply for Clarity's radioimmunotherapy (RIT) program. EirGenix's Chairman commented that RIT using copper-67 is a promising avenue for next-generation antibody therapies.
  • University of MelbourneminorStrategic or Co-development Partner · 11 February 2025Academic collaboration with the University of Melbourne on pioneering work combining trastuzumab antibody with Clarity's SAR chelator for copper-64/67 radiolabelling, resulting in the 64/67Cu-SAR-trastuzumab preclinical asset.
  • The University of Queensland (UQ) / AIBNcoreTechnology or Integration · 1 January 2025Copper-64 supply agreement with UQ's Australian Institute for Bioengineering and Nanotechnology (AIBN). The AIBN houses an on-site cyclotron and state-of-the-art radiochemistry facilities supplying copper-64 weekly to Australian clinical trial sites. Supports Phase III CLARIFY and AMPLIFY trials in Australia, the Co-PSMA IIT at St Vincent's Hospital Sydney, and the SECuRE theranostic trial. Also supports preclinical programs including SAR-bisFAP and SAR-trastuzumab.
  • ARC Hub for Advanced Manufacture of Targeted Radiopharmaceuticals (AMTAR)minorStrategic or Co-development Partner · 1 January 2024Clarity is an active participant in the Australian Research Council (ARC) Hub for Advanced Manufacture of Targeted Radiopharmaceuticals (AMTAR), a collaborative R&D initiative advancing radiopharmaceutical manufacturing in Australia.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Clarity Pharmaceuticals competitors and assessment

Company assessment

Broad incumbents

  • Novartis (Pluvicto / Lutathera franchise): Novartis commercializes Pluvicto (Lu-177 PSMA-617) for mCRPC and Lutathera for NETs — the most direct approved competitors to Clarity's SAR-bisPSMA and SARTATE. Both target the same indications with radioligand therapy, and Novartis' commercial scale and physician relationships set the competitive benchmark.
  • Bayer (Curium / PSMA-617 franchise): Bayer acquired PSMA-617 rights and operates in the PSMA radioligand space alongside its broader oncology franchise. Broad incumbent with deep capital and a radioligand therapy competing directly with Clarity's SAR-bisPSMA therapeutic program in mCRPC.
  • Bracco Imaging: Bracco is a global diagnostic imaging company with a radiopharmaceutical portfolio (including Ga-68 PSMA agents through Blue Earth Diagnostics). Broad incumbent with established imaging distribution infrastructure and overlapping prostate cancer imaging products.
  • Curium Pharma: Curium is one of the world's largest nuclear medicine companies, manufacturing and distributing diagnostic radiopharmaceuticals including SPECT and PET agents. Relevant as a manufacturing and distribution competitor for hospital/nuclear medicine supply, with established relationships that Clarity's commercial team will compete against.
  • GE HealthCare: GE HealthCare has a major radiopharmaceutical and PET imaging franchise, including manufacturing capacity and emerging theranostic partnerships. Broad incumbent whose scale in nuclear medicine supply and imaging infrastructure represents both competitive pressure and potential partnership optionality.

Direct peers

  • Telix Pharmaceuticals: Telix is the most directly comparable clinical/commercial radiopharmaceutical peer, with approved Illuccix (Ga-68 PSMA-11 PET) for prostate cancer imaging and a pipeline of PSMA-targeted therapies. Same target class, similar distribution model to hospitals/imaging centers, and overlapping indications make it Clarity's closest competitor for both share-of-voice and commercial share.
  • Lantheus Holdings: Lantheus markets Pylarify (F-18 DCFPyL) for PSMA PET imaging and has a PSMA-targeted radioligand therapy (PNT2002) in development. Direct competitor in prostate cancer imaging with established US commercial infrastructure and similar radiopharmaceutical business model.
  • POINT Biopharma: POINT Biopharma develops PSMA-targeted radioligand therapies (including PNT2002 in collaboration with Lantheus). Directly comparable as a clinical-stage radiopharmaceutical company targeting prostate cancer with Lu-177-based therapies.
  • Fusion Pharmaceuticals: Fusion Pharmaceuticals is a clinical-stage radiopharmaceutical company developing targeted alpha therapies (actinium-225) across multiple tumor types. Comparable business model, technology platform approach, and oncology focus make it a relevant emerging peer.

Emerging players

  • Actinium Pharmaceuticals: Actinium develops antibody-radionuclide conjugates for hematologic cancers using actinium-225. Comparable as a clinical-stage radiopharmaceutical company with platform technology, though focused on different isotopes and indications.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Clarity Pharmaceuticals social profiles

Digital presence

Clarity Pharmaceuticals compliance and trust

Trust signal

Compliance5 records

Clarity Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Clarity Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles9 records

Clarity Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Clarity Pharmaceuticals M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Clarity Pharmaceuticals

What does Clarity Pharmaceuticals do?

Clarity Pharmaceuticals is a clinical-stage radiopharmaceutical company developing next-generation Targeted Copper Theranostics (TCT) based on its proprietary SAR (Sarcophagine) chelator platform. Its products pair copper-64 (for diagnostic PET imaging) and copper-67 (for therapy) with tumour-targeting molecules, including SAR-bisPSMA for prostate cancer, SARTATE for neuroendocrine tumours and neuroblastoma, and SAR-Bombesin for pan-cancer indications. Upon FDA approval, finished doses will be supplied directly to hospitals, imaging centres and nuclear medicine departments.

Is Clarity Pharmaceuticals a public or private company?

Clarity Pharmaceuticals is a public company. It is classified as public and is currently operating.

When was Clarity Pharmaceuticals founded?

Clarity Pharmaceuticals was founded in 2010. It employs 51 to 100 people.

Where is Clarity Pharmaceuticals based?

Clarity Pharmaceuticals is headquartered in Sydney, Australia, in the Oceania region.

How does Clarity Pharmaceuticals make money?

One revenue line is on record: radiopharmaceutical Product Sales (Anticipated).

Who are Clarity Pharmaceuticals's main competitors?

Broad incumbents on record are Novartis (Pluvicto / Lutathera franchise), Bayer (Curium / PSMA-617 franchise), Bracco Imaging, Curium Pharma and GE HealthCare. Direct peers are Telix Pharmaceuticals, Lantheus Holdings, POINT Biopharma and Fusion Pharmaceuticals. Actinium Pharmaceuticals is listed as an emerging player.

Does Clarity Pharmaceuticals have an API?

No public API is recorded for Clarity Pharmaceuticals.

What industry is Clarity Pharmaceuticals in?

Clarity Pharmaceuticals's product category is Radiopharmaceuticals. Its primary akta.pro industry code is HLAIAGAC, Theranostic Radiopharmaceutical Platforms (Paired Dx/Tx), with a secondary code of HLAIAGAB, Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy). Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR Newswire APACRegistrational Phase III AMPLIFY trial: Follow-up assessments completed for all participantsClarity Pharmaceuticals announced that all participants in the AMPLIFY Phase III diagnostic trial of 64Cu-SAR-bisPSMA PET for prostate cancer biochemical recurrence have completed final follow-up assessments. The trial, which enrolled 220 participants, was granted Breakthrough Therapy designation by the US FDA. Topline results are expected in the first half of 2027.PR NewswireRegistrational Phase III AMPLIFY trial: Follow-up assessments completed for all participantsClarity Pharmaceuticals announced that all participants in the AMPLIFY Phase III trial of 64Cu-SAR-bisPSMA PET for prostate cancer biochemical recurrence have completed final follow-up assessments. The trial, which enrolled about 220 participants, was granted Breakthrough Therapy designation by the FDA. Topline results are expected in the first half of 2027.TradingViewClarity Pharmaceuticals: SAR-bisPSMA pairs differentiated imaging data with advancing therapy and near-term readoutsSAR-bisPSMA has received FDA breakthrough designation, with Phase III readouts approaching. Co-PSMA shows higher lesion detection than gallium PSMA-11. Development spans primary-disease imaging and copper-67 therapy, with SECuRE data expected into CY2027.Investing.comClarity Pharmaceuticals at Bell Potter Healthcare Conference: FDA win lifts outlookClarity Pharmaceuticals announced FDA breakthrough therapy designation for its second-generation PSMA imaging agent SAR-bisPSMA at the Bell Potter Healthcare Conference. The company cited Co-PSMA trial data showing 80% lesion detection versus 36% for gallium PSMA-11 in low-PSA patients, and is advancing a therapeutic version. Phase III imaging data are expected in 2027.Simply Wall StWe're Not Very Worried About Clarity Pharmaceuticals' (ASX:CU6) Cash Burn RateClarity Pharmaceuticals reported a cash burn of AU$93m in the last year, with zero debt and AU$178m in cash, giving a 23-month runway. Its cash burn rose 69% over the past year, and the company would need to issue shares to fund growth, diluting shareholders.TradingViewClarity Pharmaceuticals (CU6) Gets FDA Breakthrough Designation for Prostate ImagingThe FDA granted breakthrough therapy designation to Clarity Pharmaceuticals' 64Cu-SAR-bisPSMA for PET imaging of suspected recurrent prostate cancer. The designation follows trial data showing a 78% co-PSMA detection rate versus 36% with standard-of-care imaging. Topline results from two Phase III trials are expected in the first half of 2027.TradingViewClarity Pharmaceuticals Granted Breakthrough Therapy Designation for Prostate Cancer Copper TheranosticThe FDA granted Clarity Pharmaceuticals breakthrough therapy designation for 64Cu-SAR-bisPSMA, a copper theranostic for prostate cancer detection. The designation is based on Phase II and I/II trial data showing improved diagnostic performance over standard PSMA PET. Clarity is running two Phase III trials with topline data expected before mid-2027.The future of tradingClarity Pharmaceuticals wins FDA breakthrough designation for Cu-64 SAR-bisPSMA prostate cancer imaging agentClarity Pharmaceuticals received FDA Breakthrough Therapy designation for Cu-64 SAR-bisPSMA imaging in suspected recurrent prostate cancer on Nov. 12, 2026. The first such designation in PSMA PET imaging, supported by Co-PSMA and COBRA trial data, with Phase III trials AMPLIFY and CLARIFY completed recruitment and topline results expected in H1 2027.